Skip to search formSkip to main contentSkip to account menu

carcinoma poorly differentiated

Known as: poorly differentiated carcinoma 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Primary malignant neoplasm

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Poorly Differentiated and Undifferentiated Thyroid Carcinomas.
Thyroid cancer is the most common endocrine malignancy and its incidence goes on increasing worldwide. The majority of thyroid… 
Highly Cited
2012
Highly Cited
2012
Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice.
Previous evidence suggests soy genistein may be protective against prostate cancer, but whether this protection involves an… 
Review
2012
Review
2012
Classification of thyroid follicular cell tumors: with special reference to borderline lesions.
We propose a new classification of thyroid follicular cell tumors which is correlated with patient's prognosis. It is unique as… 
Highly Cited
2005
Highly Cited
2005
Immunoexpression of HBME-1, High Molecular Weight Cytokeratin, Cytokeratin 19, Thyroid Transcription Factor-1, and E-cadherin in Thyroid Carcinomas
To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we… 
Highly Cited
2002
Highly Cited
2002
Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.
Highly Cited
1997
Highly Cited
1997
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
PURPOSE The objectives of this study were to assess clinical outcomes and prognostic factors in unselected, consecutive patients… 
Highly Cited
1997
Highly Cited
1997
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
PURPOSE To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and… 
Highly Cited
1996
Highly Cited
1996
p53 gene mutation in thyroid carcinoma.
1992
1992
Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA) of unknown primary site… 
Review
1987
Review
1987
Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
We have previously reported complete responses and long-term survival in patients with metastatic poorly differentiated carcinoma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)